Business Description
Medexus Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA70533E1088
Total Employee Number:
91Compare
Compare
Traded in other countries / regions
MDP.CanadaMEDXF.USAP731.Germany IPO Date
2018-03-21Description
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | 1.75 | |||||
Interest Coverage | 1.12 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.93 | |||||
Beneish M-Score | -2.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.4 | |||||
3-Year EBITDA Growth Rate | -18 | |||||
3-Year Book Growth Rate | 11.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 16.91 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.07 | |||||
9-Day RSI | 69.46 | |||||
14-Day RSI | 68.42 | |||||
3-1 Month Momentum % | 2.59 | |||||
6-1 Month Momentum % | 33.71 | |||||
12-1 Month Momentum % | 30.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.19 | |||||
Quick Ratio | 0.57 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 277.95 | |||||
Days Sales Outstanding | 47.41 | |||||
Days Payable | 219.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.6 | |||||
Shareholder Yield % | 16.76 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.78 | |||||
Operating Margin % | 5.88 | |||||
Net Margin % | -2.41 | |||||
EBITDA Margin % | 12.75 | |||||
FCF Margin % | 3.63 | |||||
OCF Margin % | 18.98 | |||||
ROE % | -4.58 | |||||
ROA % | -1.52 | |||||
ROIC % | 5.46 | |||||
ROC (Joel Greenblatt) % | 172.94 | |||||
ROCE % | 3.54 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 11.4 | |||||
PE Ratio without NRI | 273.21 | |||||
Price-to-Owner-Earnings | 15.19 | |||||
PS Ratio | 1.23 | |||||
PB Ratio | 2.47 | |||||
Price-to-Free-Cash-Flow | 34.6 | |||||
Price-to-Operating-Cash-Flow | 6.54 | |||||
EV-to-EBIT | 46.31 | |||||
EV-to-EBITDA | 10.71 | |||||
EV-to-Forward-EBITDA | 6 | |||||
EV-to-Revenue | 1.36 | |||||
EV-to-Forward-Revenue | 1.12 | |||||
EV-to-FCF | 35.42 | |||||
Price-to-GF-Value | 2.96 | |||||
Price-to-Projected-FCF | 1.43 | |||||
Price-to-Median-PS-Value | 1.72 | |||||
Earnings Yield (Greenblatt) % | 2.16 | |||||
FCF Yield % | 3.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medexus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 85.371 | ||
| EPS (TTM) (€) | -0.061 | ||
| Beta | 1.5358 | ||
| 3-Year Sharpe Ratio | 0.76 | ||
| 3-Year Sortino Ratio | 1.38 | ||
| Volatility % | 52.97 | ||
| 14-Day RSI | 68.42 | ||
| 14-Day ATR (€) | 0.074519 | ||
| 20-Day SMA (€) | 2.731 | ||
| 12-1 Month Momentum % | 30.77 | ||
| 52-Week Range (€) | 1.5 - 3.14 | ||
| Shares Outstanding (Mil) | 31.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medexus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medexus Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 08:00 | In 126 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 125 days | ||
| General meeting for 2026 | 2026-09-25 10:00 | In 77 days | ||
| First quarter earnings conference call for 2027 | 2026-08-13 08:00 | In 34 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 32 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-06-26 08:00 | 2.46 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-26 08:00 | 2.46 (+0.00%) | ||
| Annual report for 2026 | 2026-06-25 | 2.46 (+0.00%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-12 08:00 | 1.70 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-02-11 | 1.69 (+0.00%) |
Show
Entries
Medexus Pharmaceuticals Inc Frequently Asked Questions
What is Medexus Pharmaceuticals Inc(FRA:P731)'s stock price today?
The current price of FRA:P731 is €3.08. The 52 week high of FRA:P731 is €3.14 and 52 week low is €1.50.
When is next earnings date of Medexus Pharmaceuticals Inc(FRA:P731)?
The next earnings date of Medexus Pharmaceuticals Inc(FRA:P731) is 2026-08-12 Est..
Does Medexus Pharmaceuticals Inc(FRA:P731) pay dividends? If so, how much?
Medexus Pharmaceuticals Inc(FRA:P731) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Sidoti Microcap Virtual Conference | 2021-05-18 | ||
| Medexus (MDP.V) expands specialty pharmaceuticals portfolio | 2020-12-21 | ||
| Medexus to Webcast Live at VirtualInvestorConferences.com December 3rd | 2020-12-02 | ||
| Medexus to Present at The LD 500 Virtual Conference on September 1st | 2020-08-25 |
Articles on Medexus Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers